c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC)

Authors :: Tomasz M. Beer
Heather H. Cheng
Delia Petreaca
George Thomas
Julie N. Graff
Dustin Kreitner
Joshi J. Alumkal
Source :: Journal of Clinical Oncology. 36:TPS5097-TPS5097
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: TPS5097Background: The management of mCRPC has been both enhanced and complicated by the rapid emergence of at least five new agents that can lengthen survival. While great strides have been made i...

Full Text Access

Tools